By Ronald G. Tompkins, MD, ScD Co-Director, The Harvard ME/CFS Collaboration in Open Medicine Foundation.
In May, 2020, Open Medicine Foundation (OMF) announced the Mestinon Clinical Trial for ME / CFS, conducted at the Brigham & Women’s Hospital by Dr. David Systrom in association with the Harvard ME / CFS Collaboration at the Harvard Affiliated Hospitals.
This study was started after Dr. Systrom observed that some people with ME / CFS have what is known as Preload Failure (PLF).
In this instance, Preload Failure is thought to come from an imbalance in the autonomic nervous system and results in reduced filling of the heart during exertion, and could be associated with postural orthostatic tachycardia syndrome (POTS) and/or post-exertion malaise (PEM).
Prior studies have shown symptomatic improvement in the general population with PLF after treatment with Mestinon.
To read the rest of this story, click on the link below: